Counteracting effects of treprostinil and endothelin (ET-1) receptor antagonists (ETRAs) on endothelin-1, ETB receptor and ECE-1 levels in pulmonary smooth muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension (PAH)  by Patel, Jigisha et al.
Inhibition of resistance artery responses to endothelins (ETs) might
be useful in therapy-resistant hypertension and stroke. ETs cause long-
lasting arterial contractions by tight binding to smooth muscle ETA
receptors. Chemically diverse ET-receptor antagonists (ERA) inhibit
binding of ET-1 to ETA and reduce sensitivity to ETs. We investigated
negative allosteric modulation by ERA in isolated rat resistance arteries.
1 μM BQ123 (cyclic pentapeptide) reversibly relaxed contractile
responses to 32 nM ET-1 to a different extent in arteries from different
vascular beds (−0 to −80%) and reduced mesenteric artery (MA)
sensitivity to ET-1 more avidly (pKB 7.6 ±0.4) than that to ET-2 (pKB
5.6 ± 0.4). This agonist-dependence was less marked with 100 nM PD-
156707 (butenolide; pKB 8.5 ± 0.3 and 7.9 ± 0.3) and not signiﬁcant
with 1 nM BMS-193884 (biphenyl sulphonamide; pKB 9.3 ± 0.1 and
9.2 ± 0.1). Effects of high concentrations of BMS-193884 on MA
sensitivity to ET-1 and ET-2 were not concentration-dependent. In the
presence of 10 nMBMS-193884, i) 1 μMBQ123 had no additional effect
but ii) 100 nM PD-156707 resulted in a further signiﬁcant reduction of
MA sensitivity to ET-1. Binding i) a ﬂuorophore to PD-156707 (useful
for diagnosis) or ii) an angiotensin AT1-antagonistic moiety to BMS-
193884 (dual antagonist PS-433540) impaired ET-antagonism by the
pharmacophores. Thus, chemically distinct ERA act differently on
resting and agonist-activated ETA receptors and display system- and
agonist-dependence and saturability (pharmacological properties of
allosteric modulation). Also, the observations suggest the presence of
several allosteric binding sites on ETA receptors, the structure-activity
relationships of which can be studied.
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Extracellular superoxide dismutase (EC-SOD), one member of SOD
family, exists outside the cells in mammals. It catalyzes conversion of
superoxide anion (O2−) into hydrogen peroxide (H2O2), destroying
free radicals upon reactive oxygen species (ROS) production to relieve
oxidative stress. In this study, a methylotrophic Pichia pastoris system
was used to produce a large-scale of recombinant human EC-SOD by
yeast fermentation. After puriﬁed by fast protein liquid chromatogra-
phy (FPLC), three different subtypes of EC-SOD were performed.
Furthermore, the spontaneously hypertensive rat (SHR) was used to
examine anti-hypertension efﬁciency among different EC-SOD isoforms
through blood pressure measurement and NO release in blood after tail
intravenous injection of EC-SOD. Results showed that different subtypes
of EC-SOD share similar secondary structure but their activity diverse.
After injection of high-dose EC-SOD into SHR, we observed obvious
decrease of blood pressure and increase of blood nitric oxide (NO)
immediately. After blocking the NO synthesis, EC-SOD lost its ability of
blood pressure regulation. Our data provided that enormous antioxi-
dant and antihypertensive activities of human EC-SOD were largely
produced by yeast fermentation. It can be applied on the extent of
health care to prevent hypertension and also cardiovascular diseases.
doi:10.1016/j.lfs.2013.12.149
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The fermented milk has antithrombotic, immunomodulatory,
antihypertensive and cardiovascular effects. In the present study,
the fermented milk and its derived peptide, 19AA, were investigated
for the ﬁrst time. Results demonstrated that the fermented milk had
a strong antihypertensive activity in spontaneous hypertension rats
(SHRs). Among two fractions derived from the fermented milk,
Fraction A exhibited the best antihypertensive activity. Following
reverse-phase high-performance liquid chromatography, a 19AA
short peptide was further puriﬁed and identiﬁed from Fraction A.
The synthetic peptide with a sequence of 19AA showed the strong
antihypertensive activity from 1 to 10 h after oral administration of
1 mg of 19AA/kg of body weight, and the effect of systolic and
diastolic blood pressure (SBP and DBP) decreasing was maximal at
44.0 ± 2.1 mmHg and 23.0 ± 2.9 mmHg, respectively, after oral
administration. The present study revealed that 19AA showed
excellent antihypertensive activity, and its activity is better than
that of VPP tripeptide which has been already included in functional
foods. In conclusion, the 19AA fermented peptide is the bioactive
ingredient with potential beneﬁt in the prevention and treatment of
hypertension or other associated disorders.
doi:10.1016/j.lfs.2013.12.150
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Background: ET-1 levels rise in PAH, correlating with increased
pulmonary vascular resistance and mortality. Lung endothelial ETB
receptors promote ET-1 clearance, which is improved in PAH
patients by epoprostenol (prostacyclin). Whether prostacyclin
analogues behaviour similarly is unclear or if smooth muscle ETB
receptors regulate ET-1 levels. Methods: Cultured human PASMCs
from PAH patients were treated for 24 h with treprostinil, an ETRA or
a combination. A chemiluminescent ELISA was used to measure ET-1
in the supernatant while ET-1 converting enzyme (ECE-1) and ETB
expression were evaluated by Westerns and immunohistochemistry
in lung sections. Results: Serum doubled ET-1 levels in HPSMCs, an
effect abolished by treprostinil (10–100 nM). In contrast, the ERTAs
(100 nM) bosentan and ambrisentan increased ET-1 levels by 100%
while BQ788 (selective ETB antagonist) by 200%. Treprostinil in
combination with these ETRAs failed to inhibit serum-induced ET-1
elevation. In contrast, BQ123 (selective ETA antagonist) did not affect
the response to serum or treprostinil. ECE-1 protein levels were
higher with BQ788 and bosentan compared to serum or treprostinil.
Furthermore, ETB expression was down-regulated by all ETRAs, but
not by treprostinil. In the smooth muscle layer of PAH lungs,
ECE-1 and ETB expression was markedly increased. Conclusion:
Treprostinil potently inhibits ET-1 levels in human PASMCs which
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are counteracted by ETRAs targeting ETB but not ETA receptors. ETB
receptors may also regulate ET-1 levels through changes in ECE-1
expression. We postulate that higher concentrations of treprostinil
may be required to reach clinical efﬁcacy in PAH when combined
with non-speciﬁc ETRAs.
doi:10.1016/j.lfs.2013.12.151
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Background: Transthoracic Doppler echocardiography (DE) is useful
for the screening of pulmonary hypertension (PH), which is often
treated by endothelin antagonist, although recent studies have
suggested that estimation of pulmonary artery pressure (PAP) by DE
is frequently inaccurate. This study aimed to examine that functional
tricuspid regurgitation (TR) with geometric alterations caused by right
ventricular dilatation is involved in the diagnostic error of echocardi-
ography for the assessment of PAP. Methods: We conducted a
retrospective cohort study of consecutive 127 patients (male, n = 58,
mean age of 55 years) who received both echocardiography and right
heart catheterization (RHC) during the 2-year period from November
2008 to October 2010. We deﬁned PH as mean PAP N 25 mmHg at rest
by RHC and “accurate estimated echocardiographic value” when it
remained within 10 mmHg of the invasive measurement. Results: A
total of 75 patients (59%)were diagnosed to have PH by RHC.When the
patients were divided into 3 groups; accurate (n= 52), over-estimate
(n= 63) and under-estimate (n= 12), the diagnosis of PH by RHCwas
42% in accurate, 68% in over-estimate, and 83% in under-estimate
groups (P = 0.004). In echocardiography, right ventricular dimension
was signiﬁcantly larger in over-estimate group (accurate, 30.0 ±
5.7 mm; over, 35.3 ± 8.6 mm; under, 32.8 ± 5.2 mm, P = 0.002), and
the severity of TR was signiﬁcantly worse in over-estimate group
(P b 0.0001). Right atrium tended to be larger in both over-estimate and
under-estimate groups than accurate group (accurate, 38.8 ± 5.7 mm;
over, 42.6 ± 8.49 mm; under, 42.7 ± 6.2 mm, P = 0.073). Conclusions:
Our results indicate that the accuracy of DE is not enough for PAP
evaluation, particularly in patients with PH associated with increased
TR grading and enlarged right heart dimension.
doi:10.1016/j.lfs.2013.12.152
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Since the discovery of ET-1, over-expression of ET-1 has been
demonstrated in patients with pulmonary arterial hypertension
(PAH). In contrast to chronic thromboembolic pulmonary hyperten-
sion (CTEPH), patients with PAH have pulmonary vasculopathy (PV).
PV leads to impaired dilatation of affected pulmonary vessels,
impeding the increase of cardiac output (CO) and stroke volume
(SV) during exercise. Peak O2 uptake shows CO, and peak O2-pulse
shows SV during cardiopulmonary exercise testing (CPX). To
investigate the increase of CO during exercise, we performed CPX
in 12 patients with PAH and 7 patients with CTEPH. Predicted peak
O2 uptake (45.5 ± 8.0 vs. 60.6 ± 13.4%, p b 0.01) and predicted peak
O2-pulse (55.6 ± 7.6 vs. 69.1 ± 6.9%, p b 0.01) were signiﬁcant
higher in CTEPH than PAH. Diffusion capacity for carbon monoxide
(%DLco: 40.3 ± 13.7 vs. 62.2 ± 13.9%, p b 0.01) was also signiﬁcantly
higher in CTEPH than PAH, however there was no correlation
between %DLco and peak O2 uptake or peak O2-pulse. While, there
was no difference in mean pulmonary arterial pressure (mPAP: 31 ±
6.8 vs. 30.1 ± 7.0 mmHg, n.s.), cardiac output (CO: 4.1 ± 0.6 vs. 4.4 ±
0.4 L/min, n.s.), and pulmonary vascular resistance (PVR: 5.2 ± 2.0 vs.
5.2 ± 2.8 wood units, n.s.) at rest. Our data indicate that, regardless of
hemodynamic, both lower peak O2 uptake and peak O2-pulse show PV
impeding the increase of CO during exercise. CPX can predict the onset
of PAH by detection of PV in early stage.
doi:10.1016/j.lfs.2013.12.153
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Introduction: Increased endothelin-1 (ET-1) is a hallmark of
pulmonary arterial hypertension (PAH), and contributes to its patho-
genesis. The factors controlling ET-1 in PAH are poorly understood.
Vascular endothelial growth factor (VEGF) blockade results in PAH-like
lesions in animal models, and has caused PAH in humans. The effects of
VEGF on ET-1 production by human lung blood microvascular
endothelial cells (HMVEC-LBl) are unknown. Methods: We exposed
HMVEC-LBl (Lonza Inc.) in-vitro to human VEGF121 (40 ng/ml) in
serum-free medium for 7 h, in the absence or presence of the VEGF
receptor antagonist, SU5416 (Cayman Chemical, 3 and 10 μM). ET-1
production was measured in the supernatant. Phosphorylation of VEGF
receptor 2 (VEGFR2) was measured by western blotting after exposure
to VEGF ± SU5416 for 5 and 10 min. Results: VEGF effectively caused
VEGFR2 phosphorylation, which was blocked by SU5416. VEGF
decreased ET-1 production by 29%. In the absence of VEGF, SU5146
increased ET-1 production, by 16% at 10 μM, and SU5146 was able to
completely abolish the VEGF effect on ET-1 production. Conclusion:
VEGF may promote vascular health by decreasing ET-1 production in
HVMEC-LBl. Blockade of VEGF signalling by SU5416 increases ET-1
levels and may thereby contribute to the pathogenesis of pulmonary
hypertension seen with VEGF blockade.
doi:10.1016/j.lfs.2013.12.154
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